LGC acquires Technopath Clinical Diagnostics

Create PDF

Feb. 5, 2021–LGC announced its acquisition of Technopath Clinical Diagnostics, expanding LGC’s position in the clinical diagnostics QC market. Technopath’s chemistry and immunoassay controls will be brought into LGC’s clinical diagnostics business unit.

Euan O’Sullivan, LGC’s president and COO, said in a press statement that Technopath’s “multiconstituent quality control products will dovetail perfectly with the calibration verification, molecular, and serology product portfolios within our clinical diagnostics business unit.”